IMS Health T-Shaped EvidenceNetworks Solid Tumours and Haematological Malignancies

T-Shaped Evidence NetworksReal-world data sources relevant to oncologyexist, but are currently underexploited.Negotiating access is time-consuming,governance must be precisely established andthe analysis of data collected from routineclinical practice is complex. To address theseissues, IMS Health is investing in the creationof T-Shaped Evidence Networks both for solidtumours and separately for haematologicalmalignancies.

“T-Shape” is a way of summarizing afundamental characteristic of real-world data: a compromise has to be made betweenbreadth and depth. Breadth can be achieved:real-world data sources can span broad, nearpopulation level cohorts, but only withminimal clinical information about eachpatient. Alternatively clinically rich, deep datacan be achieved: but only for a discretepopulation of patients typically with coverageof 5-10% of a total market population. OurEvidence Networks combine multiple ‘deep’data sources, permitting ready access to largecohorts of patients with the aim of real-world evidence generation.

IMS Health Real-World Evidence Solutions

Rang

e of

dat

a ty

pes

To create complete disease views, we usesophisticated approaches to supplement dataincluding: eCRF, ePRO, NLP and rapid customsourcing/linkage

DEEP

BROADNationally relevant databases

Augmented datasets

Population coverage

Biobanks, labs, registries

Defining clinically rich, deep dataData concerning multiple aspects of clinicalcare and disease description are integrated,date-ordered and continuously collected.

• Disease description: confirmed cancerdiagnosis, pathology, histology, tumourmutations, other biomarkers

• Related morbidities: pre-existingconditions; emerging morbidities

• Imaging data: X-ray, CT, MRI, PET

• Clinical care: consultations,hospitalizations, by specialty

• Interventions: surgery, radiotherapy, anti-cancer therapies

• Patient reported data and outcomes

IMS Health Evidence Networks are designed tospan five countries and capture >20k newcases per year.

Novel access to multi-country, clinically rich,live patient-level data

T-Shaped Data: Source Descriptions

©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.

Learn more

To find out more about our T-Shaped Evidence Networks, please contact Ashley Woolmore,Senior Principal, IMS Real-World Evidence Solutions at AWoolmore@imscg.com or DanielSimpson, Senior Principal, IMS Real-World Evidence Solutions at DSimpson@imscg.com or call +44 (0) 20 3075 4800

Accessing the IMS Health Evidence Network1

Evidence Network data sources are accessed subject to a clearly defined study protocol. Protocols cancover the analysis of a single ‘static’ cohort, or access data ‘continuously’ over a defined prospective time-series. Generally, patient-level data from Evidence Network sites do not leave the clinicalsetting. Governance of study approval is transparent, with prompt decision-making. Approvalconfers access simultaneously for all Evidence Network sites: with a choice to execute for single, ormultiple sites, single or multi-country.

Senior clinicians and researchers (Key Opinion Leaders) from the network are actively involved in the refinement of study design, results interpretation and dissemination planning, includingpublication choices.

Objective and intended value of T-Shaped Evidence Networks: Evidence Networks are designed to facilitate access to clinically rich data that are essential to highlystrategic questions in oncology, in partnership with our network members.

• Time to access: Prompt (weeks not months or years to obtain insight), reliable and transparent,due to network specific infrastructure, established governance and accumulated expertise inanalysis and interpretation

• Full view of the patient: Comprehensive, integrated data sources that allow the complete pictureof the patient, their disease and treatment

• Clinical context: Data are connected to a known setting of care; actual care pathways can belinked to observed and reported outcomes; access to narrative from treating clinicians

• Cost-effective: Evidence can be generated to a quality only otherwise available via primary datacollection using non-interventional study approaches

• Data quality: Clinical record is complete, structured data following consistent practices, patientcohorts of sufficient size

1 IMS Health shall comply with all the relevant applicable provisions of Data Protection laws and regulations

IMS Health Real-World Evidence Solutions 210 Pentonville Road, London N1 9JY, United Kingdom, Tel: +44 (0)20 3075 4800

One IMS Drive Plymouth Meeting, PA 19462, USA, Tel: +1 610 834-0800

RWEinfo@imshealth.com www.imshealth.com/rwe